Title
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Phase
Phase 1Lead Sponsor
TetraLogic PharmaceuticalsStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Lymphoma, T-Cell, CutaneousIntervention/Treatment
Remetinostat ...Study Participants
18The purpose of this study is to investigate the safety and tolerability of topical SHP141 applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients with Stage IA, IB, or IIA CTCL.
topical gelled solution
topical gelled solution
topical gelled solution
topical gelled solution
placebo for SHAPE (SHHP-141) topical gelled solution
SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
Inclusion Criteria: Histopathologically confirmed CTCL; a documented verifiable biopsy report is required. Documented clinical Stage IA, IB, or IIA CTCL. Skin lesion involvement of at least 3% of BSA accessible for topical application of study drug and biopsy. ECOG performance status of 0-2. Exclusion Criteria: CTCL with histologic evidence of folliculotropic variant or large cell transformed CTCL. Severe pruritus requiring systemic or topical treatment. Palpable lymph node ≥1.5 cm in diameter (unless the lymph node has been biopsied and has been designated as Stage IA-IIA disease). Coexistent second malignancy or history of prior solid organ malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix (CIN 3), papillary or follicular thyroid cancer that has been treated curatively, or prostate cancer that has been treated curatively). Any prior history of a hematologic malignancy (other than CTCL). History of or current major renal, hepatic, gastrointestinal, pulmonary, cardiovascular, genito-urinary or hematological disease, CNS disorders, infectious disease or coagulation disorders as determined by the Investigator. Evidence of active Hepatitis B or C or HIV. Circulating atypical cells >5%
| Event Type | Organ System | Event Term | Placebo for SHAPE (SHP-141) | SHAPE (SHP-141) 0.1% BID | SHAPE (SHP-141) 0.5% BID | SHAPE (SHP-141) 1.0% BID |
|---|
Response assessed by change in lesion severity using Composite Assessment of Index Lesion Severity (CAILS) Assessment Tool which measures clinical signs of CTCL by erythema; scaling; plaque elevation; hypo- or hyperpigmentation, each on a scale of 0-8; and lesion size (cm2), on a scale of 0 (no lesion; 0 cm2) to 18 (300 cm2). Up to five index lesions are each scored, and a subtotal CAILS score is provided for each index lesion. A total score is calculated by summing these subtotals. Response criteria measure the change in CAILS score from baseline to follow-up as follows: Complete Response (CR): 100% decrease in CAILS score; Partial Response (PR): 50% - 99% decrease in CAILS score; Stable Disease (SD): < 25% increase to < 50% decrease in CAILS score; Progressive Disease (PD) ≥ 25% increase in CAILS score.
